Marvel Biosciences Engages Novotech for Phase 1 First-in-Human Trial of MB-204 in Australia
- Marvel Biosciences signed a Letter of Intent with Novotech to conduct a Phase 1 SAD/MAD study of MB-204, a novel adenosine A2a antagonist for autism spectrum disorder and related neurodevelopmental disorders.
- Novotech will provide end-to-end clinical trial management including site selection, regulatory submissions, biostatistics, data management, and medical writing, with the SAD study expected to initiate in Q4 2026 in Australia.
- Australia's streamlined regulatory environment and 43.5% R&D tax credit on qualifying expenditures make it an attractive jurisdiction for Marvel's transition from preclinical to clinical-stage development.
Operational Impact
Novotech's engagement demonstrates continued demand for Asia-Pacific first-in-human CRO services among early-stage biotech sponsors seeking to combine regulatory efficiency with cost containment through Australia's tax credit framework.
Source: PharmaSource RSS